Patients treated with plasmapheresis: A case review from university hospital of the Canary Islands;Experiencia del Hospital Universitario de Canarias con pacientes tratados con plasmaféresis

Nefrologia

Volumn 31, Issue 4, 2011, Pages 415-434

  Hernández, M Rufino ^a   Cabrera, B Escamilla ^a   Sosa, D Álvarez ^a   Rebollo, S García ^a   Cabrera, M Losada ^a   Marrero, D Hernández ^b   González, A Álvarez ^a   Ramírez, A Torres ^a   Cruz, B Maceira ^a   Sellares, V Lorenzo ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Mortality; Renal failure and plasmapheresis; Therapeutic apheresis

Indexed keywords

ALBUMINOID;

ADOLESCENT; ADULT; AGED; BIOPSY; CASE REPORT; DIAGNOSIS RELATED GROUP; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; KIDNEY; KIDNEY DISEASE; MALE; MIDDLE AGED; MORTALITY; NEUROLOGIC DISEASE; PATHOLOGY; PLASMA; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; PREGNANCY; PREGNANCY COMPLICATION; RETROSPECTIVE STUDY; REVIEW; RHESUS ISOIMMUNIZATION; SEPTIC SHOCK; SPAIN; STATISTICS; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; BIOPSY; DIAGNOSIS-RELATED GROUPS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HOSPITALS, UNIVERSITY; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PLASMA; PLASMAPHERESIS; POSTOPERATIVE COMPLICATIONS; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; RH ISOIMMUNIZATION; SHOCK, SEPTIC; SPAIN; YOUNG ADULT;

EID: 79961113554     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Apr.10640     Document Type: Review

References (31)

1. Fridey JL, Kaplan AA. Uptodate [Internet]. Indications for threrapeutic plasma exchange [actualizado enero 4, 2008].
2. Fridey JL, Kaplan AA. Uptodate [Internet]. Prescription and technique of therapeutic plasma Exchange [actualizado febrero 15, 2006].
3. Anaya F. Aféresis terapéutica. Madrid: Ediciones Norma-Capitel, 2005;11-33.
4. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh frozan plasma, cryoprecipitate and cryosupernantat. Br J Haematol 2004;126(1):11-28.
5. Raphaël JC, Chevret S, Hughes RAC, Annane D. Tratamiento con plasmaféresis para el síndrome de Guillain-Barré (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008. Número 4. Oxford: Update Software Ltd. Disponible en: http://www.updatesoftware. com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
6. Roberts AW, Gillett EA, Fleming SJ. Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura: Outcome with plasma exchange. J Clin Apheresis 1991;6:150.
7. Pereira A, Mazzara R, Monteagudo J, Sanz C, Puig L, Martínez A, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol 1995;70:319.
8. Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC. Intervenciones para el síndrome urémico-hemolítico y la púrpura trombótica trombocitopénica (Revision Cochrane traducida). En: Biblioteca Cochrane Plus 2009. Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2009; Issue 1 Art no. CD003595. Chichester, UK: John Wiley & Sons, Ltd.).
9. Rahman T, Harper L. Plasmapheresis in nephrology: an update. Curr Opin Nephrol Hypertens 2006;15(6):603-9.
10. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003;42(6):1149-53.
11. Levy FL, Camarero Temiño V, Torres Torres G, Hijazi Prieto B. Plasmaféresis como tratamiento adyuvante en el fallo renal agudo secundario al riñón del mieloma. Nefrologia 2009;29(3):283-4.
12. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM; Canadian Apheresis Group Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005;143(11):777-84.
13. Mehta J, Semin SS. Hyperviscosity syndrome in plasma cell dyscrasias. Thromb Hemost 2003;29(5):467-71.
14. Anaya F. Therapeutic plasmapheresis and experience in Alzheimer's disease. Rev Neurol 2010;16(50)Suppl 5:S5-8.
15. De Andrés C, Anaya F, Giménez-Roldán S. Plasma immunoadsorption treatment of malignant multiple sclerosis with severe and prolonged relapses. Rev Neurol 2000;30(7):601-5.
16. Rufino Hernández JM, Cabello Moya E, González-Posada JM, Hernández Marrero D, Pérez Tamajón L. Tratamiento de inducción combinando inmunoglobulinas, plasmaféresis y rituximab en pacientes hipersensibilizados que reciben trasplante renal de cadáver. Nefrologia 2010;30(2):252-7.
17. Rodríguez-Ferrero M, Ampuero J, Anaya F. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transplant Proc 2009;41(6):2406-8.
18. Akalin E, Dinavahi R, Friedlander R, Ames S, De Boccardo G. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008;3(4):1160-7.
19. Brown CM, Abraham KA, O'Kelly P, Conlon PJ, Walshe JJ. Longterm experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc 2009;41(9):3690-2.
20. Shah A, Nadasdy T, Arend L, Brennan J, Leong N. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 2004;77(9):1399-405.
21. Eguchi Y. Plasma diafiltration for severe sepsis. Contrib Nephrol 2010;166:142-9.
22. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JWG. et al.; European Vasculitis Study Group (EUVAS). Botnar Research Centre, University of Oxford. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67(7):1004-10.
23. Walters G, Willis NS, Jonathan C. Intervenciones para el tratamiento de la vasculitis renal en adultos (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008. Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue).
24. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003;42(6):1149-53.
25. Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg) beyond immunodeficiencies and neurology. Clin Exp Immunol 2009;158(Suppl 1):23-33.
26. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or highdosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8.
27. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242-51.[Pubmed].
28. Sivakumaran P, Vo AA, Villicana R, Peng A, Jordan SC, Pepkowitz SH, et al. Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts. Clin Apher 2009;24:155-60.
29. White NB, Greenstein SM, Cantafio AW, Schechner R, Glicklich D, McDonough P, et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004;78:772-4.
30. Fehr T, Rüsi B, Fischer A, Hopfer H, Wüthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009;87:1837-41.
31. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004;4:996-1001.